James V. Cassella - Jan 30, 2023 Form 4 Insider Report for CONCERT PHARMACEUTICALS, INC. (CNCE)

Role
Chief Development Officer
Signature
/s/ Jeffrey A. Munsie, attorney-in-fact
Stock symbol
CNCE
Transactions as of
Jan 30, 2023
Transactions value $
-$84,385
Form type
4
Date filed
1/31/2023, 07:28 AM
Previous filing
Jan 9, 2023
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNCE Common Stock Sale -$84.4K -10.1K -5.41% $8.35 177K Jan 30, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2022.
F2 These shares were sold to satisfy tax obligations associated with the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.34 to $8.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.